A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
A082002 will temporarily close to new patient accrual, effective December 29, 2025, at 4:30ET.
